Price
No data yet.
Social Signal Score
Analyst Ratings
29 analystsRevenue
$480.13M+124.87%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Blair Jackson
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 2,050
- Beta
- 0.27
- Country
- IE
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 2.28
Financials
Revenue
$480.13M+124.9%Net Income
$16.29MEBITDA
$69.45M+1226.8%Free Cash Flow
$90.08MEPS (diluted)
$0.09Shares Outstanding (diluted)
176.37M+15.9%Operating Expenses
$329.62MCash & Debt
$755.46MReturn of Capital
$0.00Revenue by Segment (annual)
$1.18BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.48B | $241.66M | $1.47 |
| 2024 | $1.56B | $367.07M | $2.22 |
| 2023 | $1.66B | $355.76M | $2.14 |
| 2022 | $1.11B | $-158.27M | $-0.97 |
| 2021 | $1.17B | $-48.17M | $-0.30 |
| 2020 | $1.04B | $-110.86M | $-0.70 |
| 2019 | $1.17B | $-196.62M | $-1.25 |
| 2018 | $1.09B | $-139.31M | $-0.90 |
| 2017 | $903.37M | $-157.94M | $-1.03 |
| 2016 | $745.69M | $-208.44M | $-1.38 |
| 2015 | $628.34M | $-227.16M | $-1.52 |
| 2014 | $618.79M | $-30.06M | $-0.21 |
| 2012 | $575.55M | $24.98M | $0.19 |
| 2011 | $575.55M | $24.98M | $0.19 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from ALKS's reported EPS growth of 17.0% a year over 13 years.
- EPS in 5 years
- $3.22
- Implied price
- $61.12
- Return from $46.04
- 5.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $30.39 — -34.0% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 13 | 16 | 19 | 22 | 25 |
|---|---|---|---|---|---|
| 7.0% | -10.3% | -6.5% | -3.2% | -0.3% | 2.2% |
| 12.0% | -6.1% | -2.1% | 1.3% | 4.3% | 7.0% |
| 17.0% | -1.9% | 2.3% | 5.8% | 9.0% | 11.8% |
| 22.0% | 2.3% | 6.6% | 10.4% | 13.6% | 16.6% |
| 27.0% | 6.5% | 11.0% | 14.9% | 18.3% | 21.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
150+400.00%Social Signal Score
Mentions (13)
- Newsseekingalpha.com·19d ago·Neutral
Alkermes plc (ALKS) Q3 2026 Earnings Call Transcript Alkermes plc ( ALKS ) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Blair Jackson - President, CEO & Director Todd Nichols Joshua Reed - Senior VP & CFO Conference Call Participants Leonid Timashev - RBC Capital Markets, Research Division Graig Suvannavejh - Mizuho Securities USA LLC, Research Division Rudy Li David Amsellem - Piper Sandle…
View source ↗ - Newsmarketbeat.com·19d ago·Neutral
What Alkermes (ALKS) Said on Its Q3 Earnings Call Alkermes NASDAQ: ALKS reported third-quarter 2026 results marked by 31% year-over-year growth in proprietary product sales, while management highlighted continued investment in its orexin development portfolio across sleep, neuropsychiatric and neurological disorders.
View source ↗ - Newszacks.com·19d ago·Neutral
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newszacks.com·19d ago·Neutral
Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates Alkermes (ALKS) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to earnings of $0.49 per share a year ago.
View source ↗ - Newsbusinesswire.com·19d ago·Neutral
Alkermes plc Reports Third Quarter 2026 Financial Results DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended September 30, 2026. To view the detailed third quarter 2026 earnings press release and presentation, please visit the company's investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) today, to discuss these financial results and provi…
View source ↗ - Newsseekingalpha.com·24d ago·Positive
Alkermes Q3 Preview: The Pipeline Looks Strong, But Earnings Tell Another Story Alkermes is maintained at a 'Buy' with a $57 price target, driven by LUMRYZ's commercial momentum and a promising neuroscience pipeline. 3Q26 revenue is projected to rise 18% year-over-year but decline sequentially, with adjusted EPS expected to fall 64.3% due to elevated R&D and SG&A expenses. LUMRYZ's patient growth and LYBALVI's prescription trends are key near-term metrics, while Alixorexton's clinical progress b
View source ↗ - Newsbusinesswire.com·33d ago·Neutral
Alkermes to Report Third Quarter Financial Results on November 3, 2026 DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3, 2026 to discuss the company's third quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. caller…
View source ↗ - Newsseekingalpha.com·57d ago·Positive
…LUMRYZ's IH indication could drive incremental revenue, leveraging existing commercial infrastructure and delivering operating leverage with a limited SG&A increase. ALKS faces a 10% royalty to Jazz Pharmaceuticals on non-narcolepsy LUMRYZ sales post-March 2028, but the opportunity remains financially meaningful.
View source ↗ - Newszacks.com·61d ago·Neutral
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290 ALKS posts positive Phase I data for ALKS 7290, showing meaningful improvements in ADHD symptoms across dose levels in healthy volunteers and adults.
View source ↗ - Newsseekingalpha.com·72d ago·Positive
Alkermes: A Slow-Burning Buy Prospect On Orexin-Agonist Promise Alkermes plc is upgraded from Hold to Buy, driven by robust revenue growth, pipeline momentum, and strategic positioning in sleep and CNS disorders. Acquisition of Avadel and Lumryz launch propel >20% revenue growth in 2026; adjusted EBITDA guidance is $370–410M despite a GAAP net loss. Alixorexton's strong Phase 2 data in narcolepsy and IH, plus advancing orexin pipeline, underpin multi-billion-dollar long-term revenue potential.
View source ↗ - Newsfool.com·85d ago·Negative
Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000 The executive sold 7,576 shares. The transaction resulted in a 7% reduction in the insider's direct equity holdings.
View source ↗ - Newsbusinesswire.com·90d ago·Positive
…rology Publishes Data From Alkermes' Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1 DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the publication of data from the Vibrance‑1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in The Lancet Neurology. Alixorexton is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of NT1, narcolepsy type 2 (NT2) and idiopathic hyper…
View source ↗ - Newszacks.com·102d ago·Positive
ALKS Stock Rises 27% in 3 Months: Here's What You Should Know Alkermes gains 26.5% in three months as strong proprietary product sales and pipeline progress fuel momentum into the rest of 2026.
View source ↗
Earnings
Wed, Feb 24(in 3 months)
Consensus estimate $-0.24 per share
Typical surprise +29.8% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 3$0.09 vs $-0.08beat
- Tue, Jul 28$0.70 vs $-0.03beat
- Tue, May 5$-0.40 vs $-0.57beat
- Wed, Feb 25$0.34 vs $0.43miss
- Tue, Oct 28$0.49 vs $0.37beat
- Tue, Jul 29$0.52 vs $0.41beat
Estimates and results for ALKS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ALKS officers and directors.
- Bought
- —
- Sold
- $6.8m
0 trades
22 trades
- Gaffin David Josephsold
- Gaffin David Josephsold
- Gaffin David Josephsold
- Hopkinson Craig C.sold
- Nichols Christian Toddsold
- Nichols Christian Toddsold
- Snyderman Nancy Lynn Mdsold
- Hopkinson Craig C.sold
78 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed Oct 12, 2026 (13d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Sep 7, 2026 (39d later)Buy$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
